Nagao Saori, Taguchi Kazuaki, Sakai Hiromi, Yamasaki Keishi, Watanabe Hiroshi, Otagiri Masaki, Maruyama Toru
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto; Research Fellow of Japan Society for the Promotion of Science, Tokyo.
Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto.
Int J Nanomedicine. 2016 Oct 27;11:5611-5620. doi: 10.2147/IJN.S118185. eCollection 2016.
Carbon monoxide (CO) has attracted attention as a possible therapeutic agent for affecting anti-inflammatory and antioxidant activities. Previously, CO-bound hemoglobin vesicle (CO-HbV) was developed as a nanotechnology-based CO donor, and its safety profile and therapeutic potential as a clinically applicable carrier of CO were examined in vitro and in vivo. In the present study, the therapeutic efficacy of CO-HbV against severe acute pancreatitis was examined with secondary distal organ-injured model mice that were fed with a choline-deficient ethionine-supplemented diet. A CO-HbV treatment significantly reduced the mortality of the acute pancreatitis model mice compared to saline and HbV. Biochemical and histological evaluations clearly showed that CO-HbV suppressed acute pancreatitis by inhibiting the production of systemic proinflammatory cytokines, neutrophil infiltration, and oxidative injuries in pancreatic tissue. Interestingly, CO-HbV also diminished the subsequent damage to distal organs including liver, kidneys, and lungs. This could be due to the suppression of neutrophil infiltration into tissues and the subsequently enhanced oxidative injuries. In contrast, O-bound HbV, the inactive form of CO-HbV, was ineffective against both pancreatitis and distal organ injuries, confirming that CO was directly responsible for the protective effects of CO-HbV in acute pancreatitis. These findings suggest that CO-HbV has anti-inflammatory and antioxidant characteristics of CO and consequently exerts a superior protective effect against acute pancreatitis-induced multiorgan damage.
一氧化碳(CO)作为一种可能影响抗炎和抗氧化活性的治疗剂已引起关注。此前,已开发出一氧化碳结合血红蛋白囊泡(CO-HbV)作为基于纳米技术的CO供体,并在体外和体内研究了其作为临床上适用的CO载体的安全性和治疗潜力。在本研究中,利用喂食胆碱缺乏且补充乙硫氨酸饮食的继发性远端器官损伤模型小鼠,研究了CO-HbV对重症急性胰腺炎的治疗效果。与生理盐水和HbV相比,CO-HbV治疗显著降低了急性胰腺炎模型小鼠的死亡率。生化和组织学评估清楚地表明,CO-HbV通过抑制全身促炎细胞因子的产生、中性粒细胞浸润以及胰腺组织中的氧化损伤来抑制急性胰腺炎。有趣的是,CO-HbV还减轻了对包括肝脏、肾脏和肺在内的远端器官的后续损伤。这可能是由于抑制了中性粒细胞向组织的浸润以及随后增强的氧化损伤。相比之下,CO-HbV的无活性形式——氧结合血红蛋白囊泡(O-HbV)对胰腺炎和远端器官损伤均无效,这证实了CO直接负责CO-HbV在急性胰腺炎中的保护作用。这些发现表明,CO-HbV具有CO的抗炎和抗氧化特性,因此对急性胰腺炎诱导的多器官损伤具有卓越的保护作用。